|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
AU2012253571A1
(en)
|
2011-05-09 |
2014-01-09 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
CN113318239B
(zh)
|
2014-06-13 |
2025-05-30 |
梅约医药教育及研究基金会 |
治疗淋巴瘤
|
|
KR20210125603A
(ko)
|
2014-06-16 |
2021-10-18 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
골수종의 치료
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
SG10201810615VA
(en)
|
2015-02-26 |
2019-01-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
GB201509338D0
(en)
|
2015-05-29 |
2015-07-15 |
Bergenbio As |
Combination therapy
|
|
US10869924B2
(en)
|
2015-06-16 |
2020-12-22 |
Merck Patent Gmbh |
PD-L1 antagonist combination treatments
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
US11571469B2
(en)
|
2016-01-07 |
2023-02-07 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
|
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
AU2017238119A1
(en)
|
2016-03-21 |
2018-10-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
US11878061B2
(en)
|
2016-03-21 |
2024-01-23 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
EP3481422A1
(en)
*
|
2016-07-06 |
2019-05-15 |
Pierre Fabre Medicament |
Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
|
|
JP2019526579A
(ja)
|
2016-09-01 |
2019-09-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ |
Ｔ細胞癌を標的とする為の方法及び組成物
|
|
RU2019109211A
(ru)
*
|
2016-09-01 |
2020-10-01 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
|
|
EP3510048A1
(en)
*
|
2016-09-06 |
2019-07-17 |
Mayo Foundation for Medical Education and Research |
Methods of treating pd-l1 expressing cancer
|
|
WO2018048958A1
(en)
|
2016-09-06 |
2018-03-15 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
EP3571231A4
(en)
|
2017-01-20 |
2020-12-02 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
ANTI-PD-1 ANTIBODIES AND THEIR USES
|
|
MX2019009772A
(es)
*
|
2017-02-21 |
2019-12-02 |
Regeneron Pharma |
Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
|
|
JP7082110B2
(ja)
|
2017-03-29 |
2022-06-07 |
テルモ株式会社 |
アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
|
|
IL271888B2
(en)
*
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
BR112020005814A2
(pt)
*
|
2017-10-03 |
2020-09-24 |
Crititech, Inc. |
administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
|
|
CA3077664A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2019108951A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for inhibiting dhhc-type palmitoyltransferases for cancer treatment
|
|
EP3768713A2
(en)
|
2018-03-22 |
2021-01-27 |
Keires AG |
Antagonistic pd-1, pd-l1 and lag-3 binding proteins
|
|
WO2019228514A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
|
WO2020015722A1
(en)
*
|
2018-07-19 |
2020-01-23 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies, dosages and uses thereof
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
JP2022518399A
(ja)
|
2019-01-14 |
2022-03-15 |
ジェネンテック， インコーポレイテッド |
Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
|
|
CN113795511B
(zh)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
抗pd-l1双抗体及其用途
|
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
BR112022015077A2
(pt)
|
2020-01-31 |
2022-10-04 |
Genentech Inc |
Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
US20220153842A1
(en)
|
2020-11-04 |
2022-05-19 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
CA3202523A1
(en)
|
2020-12-02 |
2022-06-09 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
|
EP4377350A2
(en)
|
2021-07-28 |
2024-06-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
MX2024003037A
(es)
*
|
2021-09-10 |
2024-07-30 |
Health Hope Pharma Ltd |
Combinaciones terapéuticas de paclitaxel administrado por vía oral, un inhibidor de p-gp, y un inhibidor de punto de control para el tratamiento de tumores sólidos.
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
JP2024541508A
(ja)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
治療用インダゾール化合物およびがんの治療における使用方法
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2023144973A1
(ja)
|
2022-01-27 |
2023-08-03 |
中外製薬株式会社 |
抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3251472A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
CN119585308A
(zh)
|
2022-07-13 |
2025-03-07 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
KR20250122520A
(ko)
|
2022-12-20 |
2025-08-13 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2024268933A1
(en)
|
2023-05-10 |
2025-11-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods and compositions for treating cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|